Sangamo Therapeutics (SGMO) Return on Sales (2016 - 2025)
Sangamo Therapeutics (SGMO) has 16 years of Return on Sales data on record, last reported at 60.12% in Q3 2025.
- For Q3 2025, Return on Sales fell 6034.0% year-over-year to 60.12%; the TTM value through Sep 2025 reached 3.42%, down 84.0%, while the annual FY2024 figure was 1.69%, 23.0% down from the prior year.
- Return on Sales reached 60.12% in Q3 2025 per SGMO's latest filing, down from 1.09% in the prior quarter.
- Across five years, Return on Sales topped out at 0.22% in Q3 2024 and bottomed at 102.06% in Q1 2024.
- Average Return on Sales over 5 years is 18.2%, with a median of 2.16% recorded in 2021.
- Peak YoY movement for Return on Sales: tumbled -10219bps in 2024, then surged 10039bps in 2025.
- A 5-year view of Return on Sales shows it stood at 2.16% in 2021, then grew by 12bps to 1.91% in 2022, then plummeted by -1448bps to 29.53% in 2023, then skyrocketed by 88bps to 3.6% in 2024, then plummeted by -1570bps to 60.12% in 2025.
- Per Business Quant database, its latest 3 readings for Return on Sales were 60.12% in Q3 2025, 1.09% in Q2 2025, and 4.75% in Q1 2025.